Lilly to Pay $1.4 Billion for Cancer-Drug Maker Point Biopharma

France Nouvelles Nouvelles

Lilly to Pay $1.4 Billion for Cancer-Drug Maker Point Biopharma
France Dernières Nouvelles,France Actualités
  • 📰 BNNBloomberg
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 50%

Eli Lilly & Co. said it will pay about $1.4 billion to acquire Point Biopharma Global Inc. to gain radiation therapies in development for illnesses such as prostate cancer.

Nova Scotia May Be Hit With Second Tropical Storm: Weather WatchOil holds loss below US$90 with market buffeted by rate fearsExplosion at Food Recycling Plant Puts Spotlight on UK’s Biogas IndustryEni’s Africa Biofuel Feedstock Plan to Cost €700 MillionOPEC+ Shows No Sign of Easing Oil Squeeze as Ministers MeetIndia’s Northern Arc Eyes $100 Million Green Private Credit FundFrance Bird Flu Vaccine Plan Risks Spooking Foie Gras LoversCopper Extends Retreat to Below $8,000 for First Time Since...

2 billion deficit between April and July: Finance Department​There are risks to sharing your spouse's debt: expertStatistics Canada says job vacancies continued to fall in JulyCanadian economy to get 'back on its feet' next year, Deloitte Canada saysBank of Canada hikes likely won’t continue into 2024: expertWage wins could inspire more labour action: RBC reportTory Latest: Sunak Says He’ll ‘Look at the Facts’ on HS2 RailHow the Weapon Dissident Matt Gaetz Is Aiming at McCarthy...

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

BNNBloomberg /  🏆 83. in CA

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

U.S. FDA declines to approve Eli Lilly's skin disease drugU.S. FDA declines to approve Eli Lilly's skin disease drug(Reuters) - The U.S. Food and Drug Administration has declined to approve Eli Lilly's drug to treat a type of skin disease due to certain findings ...
Lire la suite »

U.S. FDA declines to approve Eli Lilly's skin disease drugU.S. FDA declines to approve Eli Lilly's skin disease drug(Reuters) - The U.S. Food and Drug Administration has declined to approve Eli Lilly's drug to treat a type of skin disease due to certain findings ...
Lire la suite »

Nicolas Dominguez's debut goal earns EPL point for 10-man Nottingham Forest against BrentfordNicolas Dominguez's debut goal earns EPL point for 10-man Nottingham Forest against BrentfordNicolas Dominguez scored his first goal for 10-man Nottingham Forest as the hosts held on for a 1-1 draw against Brentford on Sunday in the Premier League.
Lire la suite »

South Africa secures bonus-point win over Tonga as Pollard makes promising returnSouth Africa secures bonus-point win over Tonga as Pollard makes promising returnSouth Africa secured a bonus-point 49-18 win over Tonga that put it on the verge of the quarterfinals on Sunday, and a successful return to action for flyhalf Handre Pollard added up to a solid day out for the defending champion at the Rugby World Cup.
Lire la suite »

The Talking Point: Who is the best Canadian born goalie in the NHL?The Talking Point: Who is the best Canadian born goalie in the NHL?The era of Canada producing elite goaltenders is in the past but that's not to say that our country is incapable of developing winners. TSN Hockey analyst Martin Biron shares a few names that could be considered to be the best Canadian born goalies in the NHL right now.
Lire la suite »



Render Time: 2025-03-03 21:43:43